Pnina Fishman on finance

About Pnina Fishman

Pnina Fishman, CEO and founder of Can-Fite Biopharma, has presented company updates in multiple investor webinars and conferences between 2022 and 2025. She stated that the company has signed seven out-licensing agreements, receiving $20 million in upfront non-dilutive payments, with an additional $130 million expected from regulatory and sales milestones. Fishman noted that as of early 2025, the company had approximately $8 million in cash, which she said should support operations for 16 to 18 months. She described ongoing enrollment in a Phase III trial for Namodenoson in advanced liver cancer and a Phase IIb trial in NASH, and said the company is planning a Phase IIa study in pancreatic cancer. Fishman also reported that a Phase III trial for Piclidenoson in psoriasis had completed enrollment and that topline results were expected. Fishman has characterized Can-Fite’s drugs as orally bioavailable small molecules that target the A3 adenosine receptor, which she said is present only in pathological cells. She cited a published comparison suggesting Piclidenoson showed sustained efficacy beyond 12 weeks compared to Otezla, and described a liver cancer patient who, she said, had been treated for over seven years and was considered cured. Fishman stated that the company’s strategy is to develop and register drugs but not to market them, relying on partnerships for commercialization. She acknowledged that the share price did not reflect the pipeline in her view, and expressed confidence that positive clinical data would be reflected in the stock price.

Profile compiled from Pnina Fishman's verified public interviews and appearances. See all quotes & transcripts →